The Pharma Data

OCTOBER 29, 2020

ULTOMIRIS – Atypical Hemolytic Uremic Syndrome (aHUS): In September 2020 , Japan’s MHLW approved ULTOMIRIS for adults and children with aHUS. FDA approved the ULTOMIRIS 100 mg/mL formulation for PNH and aHUS. A global Phase 3 study of ULTOMIRIS in children and adolescents with aHUS is underway.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

pharmaphorum

JUNE 22, 2021

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly’s rival therapy Jardiance. .

Sales 98

Sales Marketing FDA Approval Trials 98

pharmaphorum

JANUARY 12, 2021

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. Farxiga won FDA approval for adults with HFrEF in May 2020, which helped to drive its third-quarter sales up by a third to $525 million.

Sales 76

Sales FDA Approval Trials Marketing 76

pharmaphorum

JULY 19, 2021

BMS filed for FDA approval of the drug on the strength of that data, and a verdict from the US regulator is due by 28 January next year.

FDA Approval 98

FDA Approval Drugs Trials Regulation 98

pharmaphorum

AUGUST 18, 2021

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with reduced ejection fraction (HFreF), setting up a market tussle with AstraZeneca’s Farxiga.

Cardiology 52

Cardiology Sales Marketing FDA Approval 52

The Pharma Data

NOVEMBER 4, 2020

In the process of hiring select people with extensive commercial experience in Europe and preparing for post-approval market access negotiations. Securities and Exchange Commission Regulation G. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology. 500 mg/dL) hypertriglyceridemia.

Sales 40

Sales Production Marketing Cardiology 40

XTalks

AUGUST 2, 2023

Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

FEBRUARY 24, 2022

Jardiance is also approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of death and hospitalization in patients with heart failure and low ejection fraction. Source link: [link].

FDA Approval 52

FDA Approval Cardiology Cosmetics Production 52

pharmaphorum

JANUARY 5, 2021

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed.

Sales 105

Sales Marketing Production Vaccination 105

The Pharma Data

APRIL 26, 2021

New approvals. Topline results will be presented at the American College of Cardiology 70th Annual Scientific Session. Exjade/Jadenu. Top 20 products total. R&D update – key developments from the first quarter. Entresto. . The safety profile of Entresto was confirmed. Novartis will continue to evaluate the data.

Sales 40

Sales Medicine Production Manufacturing 40